Suchergebnisse - "muscular dystrophy"

PubPharm (13.178)

71

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) : A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy

enthalten in: ClinicalTrials.gov | 2024

72

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy : A PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHY

enthalten in: ClinicalTrials.gov | 2024

73

A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) : A Two-Part, Open-Label Systemic Gene Delivery Study to Evaluate the Safety and Expression of RO7494222 (SRP-9001) in Subjects Under the Age of Four With Duchenne Muscular Dystrophy

enthalten in: ClinicalTrials.gov | 2024

74

Electron microscopic analysis of the influence of iPSC-derived motor neurons on bioengineered human skeletal muscle tissues

enthalten in: Cell and tissue research | 2024

von Nguyen, C. | Chávez-Madero, C. | Jacques, E. | +5

75

The extracellular matrix differentially directs myoblast motility and differentiation in distinct forms of muscular dystrophy : Dystrophic matrices alter myoblast motility

enthalten in: Matrix biology : journal of the International Society for Matrix Biology | 2024

von Long, A. | Kwon, J. | Lee, G. | +9

76

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) : A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)

enthalten in: ClinicalTrials.gov | 2024

77

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) : A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B

enthalten in: ClinicalTrials.gov | 2024

78

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) : A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B

enthalten in: ClinicalTrials.gov | 2024

79

Muscle strength, quantity and quality and muscle fat quantity and their association with oxidative stress in patients with facioscapulohumeral muscular dystrophy : Effect of antioxidant supplementation

enthalten in: Free radical biology & medicine | 2024

von Wilson, V. | Bommart, S. | Passerieux, E. | +7

80

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy : A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

enthalten in: ClinicalTrials.gov | 2024